Search
ASGCT 2025: The Co-Founder of ProQR discusses the company's Axiomer RNA base editing technology - which will see a CTA filed this quarter and data by the end of the year
ProQR Co-Founder & CSO Gerard Platenburg describes the company's RNA editing platform and the journey he has seen this field go through...
May 15, 2025
ASGCT 2025: Capsida Biotherapeutics is using its expertise in capsid design to develop gene therapies that are tissue specific, and in the case of the CNS, can be delivered via IV and crosses the BBB
CEO Peter Anastasiou describes the importance of capsid design and how Caspida is developing its own gene therapies for CNS conditions. A...
May 14, 2025
ASGCT 2025: The co-founders of Circio describe the properties they believe make circular RNA a better, more durable medium for use in gene and cell therapies
CEO Erik Wiklund and CTO Thomas Hansen describe what circular RNA is, and explain their groundbreaking work where they discovered...
May 14, 2025
Gene therapies expert TJ Cradick previews what to watch for at the 2025 ASGCT Annual Meeting in New Orleans
He discusses the clinical programs, delivery vehicle advances, and safety improvements to watch for this year as the field of cell and...
May 13, 2025
Inductive Bio raised a $25M series A last week to continue its work utilizing AI to help drug developers in discovery understand a small molecule's ADMET properties before it is synthesized
Co-Founder & CEO Josh Haimson describes the pre-competitive data consortium that is harnessed by Inductive's Compass platform to do this...
May 13, 2025
NewLimit raised a $130M series B round last week to advance its work using epigenetic reprogramming to improve cell function and thus aim to extend longevity
Co-Founder & President Jacob Kimmel and Head of Operations Cathy O'Hare describe the scientific approach and how it benefits from the...
May 12, 2025
Biotech investor Christoph Broja of EQT Life Sciences discusses biotech in Europe and highlights portfolio companies Tubulis, Agomab Therapeutics, and PanTera
He describes the current environment for life sciences in Europe and how far it has come over the last ten years. Plus, his thoughts on...
May 9, 2025
With a phase 3 trial for its PRAME cell therapy underway and a data update coming up at ASCO, Immatics is pushing to be a leader in TCR based cell therapies and T-cell engagers
CEO Harpreet Singh joins us from the company's office in Munich, Germany, where he describes the founding of the company and previews...
May 9, 2025
Mosaic Therapeutics, which uses advanced computational methods and next-generation cancer models to design novel combination therapies, licensed an ERK1/2 and MDM2 inhibitor from Astex Pharmaceuticals
Interim CEO Magda Jonikas describes Mosaic's platform and the rationale behind these two targets the company has licensed in.
May 9, 2025
Cambridge, UK based Epitopia is helping Merck (MSD) discover tumor associated antigens from the non-coding regions of the genome using its CryptoMap platform
CEO Alan Rigby talks about the work Epitopia does finding "Crypotgen" antigens for its own off-the-shelf cancer vaccines, and discusses...
May 8, 2025
Munich based Tubulis is working on ADCs that it believes are more durable, potent, and homogenous than others on the market currently - it has signed partnerships with Gilead and Bristol
Co-Founder and CEO Dominik Schumacher describes what he thinks can be improved on from the current generation of antibody-drug...
May 8, 2025
As the field builds on the initial success of PARP inhibitors, Artios Pharma is working on the next generation of DNA Damage Response (DDR)-based therapies - it just had clinical data on one at AACR
CEO Niall Martin walks us through the current state of this corner of drug development, and then highlights data presented at AACR last...
May 8, 2025
Munich based ITM Radiopharma is progressing towards a first NDA in the U.S. with a robust pipeline behind it - all the while making investments in isotope manufacturing that has slowed others
CEO Andrew Cavey describes how ITM has been investing to avoid the shortages others have experienced, and explains how the supply chain...
May 8, 2025
Off-Target Effects Episode 3: Matt speaks with STAT News' Adam Feuerstein about the dynamics of biotech journalism and how it compares to other industries
Adam shares his background of previously covering the tech industry, and compares and contrasts it to covering biotech. He describes his...
May 7, 2025
Munich based Ethris is developing a proprietary mRNA and lipid nanoparticle combination that is stable and allows for nasal administration or to be inhaled via nebulization
CEO Carsten Rudolph and CMO Thomas Langenickel describe the technology, which can be spray dried and shipped in a dry powder formulation,...
May 7, 2025
Swiss Biotech Day: Geneva based Light Chain Bioscience is developing bi-specifics that integrate two light chains into its structure with the goal of having a more native format
CEO Nicolas Fischer describes the rationale of designing bi-specifics this way, and walks us through the company's programs, which mostly...
May 6, 2025
Swiss Biotech Day: Milan based Genenta Science recently raised €20 million from a government investment fund as it takes its cell therapy into the clinic in renal cell carcinoma
Co-Founder and CEO Pierluigi Paracchi describes the terms of the convertible bond raise, which gives the investor, ENEA Tech and...
May 6, 2025
Swiss Biotech Day: Lausanne based Tigen Pharma is building out decentralized CAR-T manufacturing capabilities with global partners - it already has a program with Memorial Sloan Kettering
Chairman & CEO Emmanuel Savioz describes the benefits of decentralized manufacturing that is at or near the site of treatment. He...
May 6, 2025
Swiss Biotech Day: Lausanne based Vandria is focused on rejuvenating cells in age-related and chronic disease by inducing the removal of damaged mitochondria
CEO Klaus Dugi describes why the company is focused on mitochondria and how it using small molecules to fix them. He covers the three...
May 6, 2025
Swiss Biotech Day: Basel based BioVersys successfully completed an approximately CHF 80 million IPO in February to advance its work in antimicrobial resistance
Co-Founder & CEO Marc Gitzinger describes the success factors behind the IPO and walks us through the company's two lead programs. Plus,...
May 6, 2025
.png){kind=logo}
